Earnings ·
AIM ImmunoTech Inc. reported financial results for the quarter ended June 30, 2026, showing cash and cash equivalents…
AIMIAIM ImmunoTech Inc.
AIM ImmunoTech Inc. reported financial results for the quarter ended June 30, 2026, showing cash and cash equivalents of $9.9 million as of June 30, up from approximately $3.0 million at year-end 2025. The company incurred a net loss of approximately $3.8 million, or $0.43 per share, compared to a net loss of $2.8 million, or $3.68 per share, in the same period last year. Research and development expenses decreased to approximately $589,000 from $1.2 million, while general and administrative expenses increased to $2.9 million from $1.5 million. Operationally, AIM completed patient enrollment and dosing in its Phase 2 DURIPANC trial for metastatic pancreatic cancer using Ampligen combined with Imfinzi. The company anticipates clinical benefit data in Q1 2027 and overall survival data in Q3 2027, while maintaining compliance with NYSE American listing standards. AIM ImmunoTech Inc. is an immuno-pharmaceutical company focused on developing Ampligen for late-stage pancreatic cancer and infectious diseases.